Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

PRFX

PainReform Ltd

Jun 14 • 04:00PM ET

0.5200

Dollar change -0.0302
Percentage change -5.49	%

Healthcare • Drug Manufacturers - Specialty & Generic • Israel • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.21	Insider Own	22.13%	Shs Outstand	2.47M	Perf Week	-17.46%
Market Cap	1.28M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	0.00%	Shs Float	1.93M	Perf Month	-35.01%
Income	-12.54M	PEG	-	EPS next Q	-1.04	Inst Own	7.20%	Short Float	0.82%	Perf Quarter	-71.74%
Sales	0.00M	P/S	-	EPS this Y	50.98%	Inst Trans	0.92%	Short Ratio	0.08	Perf Half Y	-79.03%
Book/sh	1.00	P/B	0.52	EPS next Y	42.29%	ROA	-158.88%	Short Interest	0.02M	Perf Year	-89.73%
Cash/sh	1.75	P/C	0.30	EPS next 5Y	-	ROE	-233.54%	52W Range	0.55 - 26.41	Perf YTD	-81.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.81%	ROI	-673.22%	52W High	-98.03%	Beta	0.64
Dividend TTM	-	Quick Ratio	1.61	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-5.45%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.61	EPS Y/Y TTM	6.97%	Oper. Margin	0.00%	RSI (14)	31.94	Volatility	15.53% 11.95%
Employees	7	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-26.22%	Payout	-	Rel Volume	1.62	Prev Close	0.55
Sales Surprise	-	EPS Surprise	-45.83%	Sales Q/Q	-	Earnings	May 13	Avg Volume	208.47K	Price	0.52
SMA20	-26.13%	SMA50	-41.42%	SMA200	-75.76%	Trades		Volume	337,652	Change	-5.49%

Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -5.49%
May-31-24 04:15PM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-15-24 10:54PM	PRFX Stock Earnings: PainReform Misses EPS for Q1 2024 (InvestorPlace) -6.31%
04:05PM	PainReform Provides Business Update for the First Quarter of 2024 (GlobeNewswire)
May-08-24 08:30AM	PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com (GlobeNewswire) -6.43%
02:19PM	Loading…
Apr-18-24 02:19PM	PainReform Announces Closing of $4 Million Public Offering (GlobeNewswire)
Apr-16-24 08:00AM	PainReform Announces Pricing of $4 Million Public Offering (GlobeNewswire) -17.42%
Apr-09-24 10:30AM	EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions (Benzinga) -13.21%
09:00AM	PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions (GlobeNewswire)
Apr-02-24 10:00AM	EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug (Benzinga)
08:30AM	PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-01-24 08:00AM	PainReform Provides Year-End Business Update (GlobeNewswire) +21.42%
Jan-22-24 08:30AM	PainReform to Present at the Microcap Conference in Atlantic City (GlobeNewswire) -7.37%
Jan-03-24 08:30AM	PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief (GlobeNewswire)
Dec-26-23 06:00PM	PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds (GlobeNewswire)
04:05PM	Loading…
Nov-15-23 04:05PM	PainReform Provides Business Update for the Third Quarter of 2023 (GlobeNewswire) -5.33%
Sep-11-23 08:30AM	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File (GlobeNewswire)
Sep-07-23 10:00AM	PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary (GlobeNewswire) +6.37%
Sep-05-23 08:30AM	PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City (GlobeNewswire) -7.56%
Aug-10-23 04:05PM	PainReform Provides Business Update for the Second Quarter of 2023 (GlobeNewswire)
06:45AM	7 Stocks Under $10 to Buy for August (InvestorPlace)
Jul-19-23 09:00AM	PainReform Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire) -8.02%
Jul-14-23 02:35PM	PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) +40.87%
Jul-12-23 09:05AM	PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -51.58%
Jul-03-23 09:01AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.) +17.33%
Jun-15-23 08:30AM	PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st (GlobeNewswire)
Jun-07-23 04:30PM	PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-18-23 09:00AM	PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire)
May-15-23 04:45PM	PainReform Provides Business Update for the First Quarter of 2023 (GlobeNewswire)
May-02-23 08:30AM	PainReform CEO to Present at Aegis Virtual Conference on May 4th (GlobeNewswire) -6.26%
08:30AM	Loading…
May-01-23 08:30AM	PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +17.02%
Apr-17-23 09:00AM	PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th (GlobeNewswire)
Mar-28-23 09:10AM	PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) -10.62%
Mar-16-23 08:00AM	PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy (GlobeNewswire)
Mar-14-23 08:00AM	PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery (GlobeNewswire) +19.86%
Feb-07-23 04:05PM	PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaqs Minimum Bid Price Requirement (GlobeNewswire)
Nov-15-22 08:30AM	PainReform Provides Business Update for the Third Quarter of 2022 (GlobeNewswire)
Nov-08-22 08:30AM	PainReform Provides Further Update on Manufacturing of PRF-110 (GlobeNewswire)
Oct-04-22 09:00AM	PainReform Provides PRF-110 Manufacturing Update (GlobeNewswire)
Sep-01-22 08:00AM	PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.03%
Aug-16-22 08:05AM	PainReform Provides Business Update for the Second Quarter of 2022 (GlobeNewswire)
08:00AM	PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-22 07:00AM	PainReform Provides Business Update for the First Quarter of 2022 (GlobeNewswire) +12.84%
Apr-12-22 09:00AM	PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th (GlobeNewswire)
Mar-21-22 09:25AM	PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th (GlobeNewswire) +39.64%
Mar-17-22 08:00AM	PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 (GlobeNewswire) -14.17%
Dec-14-21 08:30AM	PainReform CEO to Participate in the Benzinga All Access Event on December 16th (GlobeNewswire) -5.36%
Nov-22-21 11:58AM	PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today (InvestorPlace)
07:02AM	Will PainReform (NASDAQ:PRFX) Spend Its Cash Wisely? (Simply Wall St.)
Nov-16-21 08:00AM	PainReform Provides Business Update for the Third Quarter of 2021 (GlobeNewswire) -9.45%
Oct-14-21 08:30AM	PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Aug-16-21 08:00AM	PainReform Provides Business Update for the Second Quarter of 2021 (GlobeNewswire) -5.58%
Jun-15-21 12:46PM	Is PainReform Ltd. (PRFX) A Good Stock To Buy Now? (Insider Monkey) -6.95%
May-24-21 06:35AM	We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate (Simply Wall St.)
May-13-21 08:15AM	PainReform Provides Business Update for the First Quarter of 2021 (GlobeNewswire) +5.58%
Mar-18-21 09:15AM	PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief (GlobeNewswire) -11.82%
Mar-11-21 10:43AM	PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference (GlobeNewswire)
Mar-08-21 09:00AM	PainReform Announces $6.0 Million Private Placement (GlobeNewswire)
Jan-07-21 08:30AM	PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Jan-06-21 08:30AM	PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations (GlobeNewswire) -5.17%
Jan-04-21 08:30AM	PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 (ACCESSWIRE)
Nov-23-20 08:30AM	PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer (ACCESSWIRE) +10.34%
Nov-12-20 09:00AM	PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors (ACCESSWIRE)
Nov-05-20 08:30AM	PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors (ACCESSWIRE)
Oct-19-20 09:00AM	PainReform Highlights Surgical Advantages of PRF-110 (ACCESSWIRE)
Sep-29-20 07:30AM	PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials (ACCESSWIRE)
Sep-09-20 02:15PM	PainReform Announces Closing of $20.0 Million Initial Public Offering (ACCESSWIRE)

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRFX

PainReform Ltd

Upgrade your FINVIZ experience